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Figure S1. Inhibitory effect of Nic on poorly and well differentiated PC cell lines. Concentra-
tion (1, 5, 10 and 20 µM) and time-dependent (24 and 48 h) effect of Nic treatment on viability 
of poorly differentiated (PANC-1, MIAPaCa-2) and well differentiated (Capan-1) pancreatic 
cell lines was determined by MTT assay. Values are expressed as mean ± SEM (n=6), p values: 
***p < 0.001, *p < 0.05 vs control (24 h); ###p < 0.001 vs control (48 h). 
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Figure S2. Nic-mediated inhibition of migration potential in PC cell lines. (A) Nic-treated COLO 357, SW1990, and T3M4 cells were 
analyzed for their migration potential. A total of 1×105 cells were seeded into top chamber of the trans-well with serum-free media, 
whereas, bottom chamber with serum containing media, and after 24 h, migrated cells were stained and analyzed. (B) Representa-
tive western blots showing the expression of protein markers involved in migration and EMT transition such as E-cadherin, N-








Figure S3. The efficacy of Nic on pancreatic cancer-associated fibroblasts. (A) The effect of Nic on viability of cancer-associated 
fibroblast cell lines (09-11, 09-17, 10-32, 10-15, 10-03CAFs) and normal fibroblast (09-26N) were determined by MTT assay. Val-
ues are expressed as mean ± SEM(n=6), p values: ***p < 0.001, **p < 0.001, *p < 0.05 vs control (24 h); ###p < 0.00, ##p < 0.001, #p < 
0.05 vs control (48 h) (B) Representative western blot image showing the expression of α-SMA and FAPα in 10-32 CAFs cells 
treated with Nic (10 µM) for 24 h. 






Figure S4. Analysis of PARP expression in PC cell lines upon Nic treatment. Densitometric quantitation of western blot results 
shown as percentage protein expression of full-length PARP, cleaved PARP, and the ratio of cleaved to full-length PARP in 
COLO 357 and SW1990 cells treated with Nic (10 µM) for various time periods i.e., 1, 3, 12, 24, and 48 h. Values are expressed 
as mean ± SEM (n = 3), p values: ***p < 0.001, **p < 0.001, *p < 0.05, nsp >0.05 vs control. 
 
 
Figure S5. Effect of Nic on the Cleaved caspase-3 expression in PC cell lines. Representative western blot images showing the ex-
pression of Cleaved caspase-3 in COLO 357 and SW1990 PC cell lines treated with Nic (10 µM) for 24 h and 48 h and observed time 
dependent increase of cleaved caspase-3 expression in PC cell lines. 




Figure S6. Nic exhibits growth suppression in poorly differentiated PC cell lines and pancreatic cancer-associated fibro-
blasts (CAFs) by inducing apoptosis. (A) Poorly differentiated PC cell lines (PANC-1 and AsPC-1) and (B) pancreatic 
cancer associated fibroblast cell line (10-32 CAFs) were treated with Nic (5 and 10 µM) for 24 h, and induction of apoptosis 
was determined by flow cytometric analysis of annexin-V Cy-5/PI- dual stained cells (AV+/PI–intact cells; AV/PI+–nonvi-
able/necrotic cells; AV+/PI and AV+/PI+ – apoptotic cells) in PC cell lines (left panel). Quantitative analysis of these micro-
graphs was shown as mean ± SEM (n = 3), p values: ***p < 0.001, **p < 0.01 vs live control cells; ###p < 0.001vs apoptotic 
control cells (right panel). 




Figure S7. Nic stimulates the expression of a lipidated form of LC3B in PC cell lines. Densitometric quantitation of western 
blotting images was shown as percentage protein expression of LC3I, LC3 II, and LCII/I in COLO 357 and SW1990 cells 
treated with Nic (10 µM) for various time periods i.e., 1, 3, 12, 24, and 48 h. Values are expressed as mean ± SEM(n=3), p 
values: ***p < 0.001, **p < 0.001, *p < 0.05, nsp >0.05 vs control. 
  
 
Figure S8. Effect of functional blockage autophagy via spautin-1 on Nic- mediated growth suppression via Calcein AM assay. 
COLO 357 and SW1990 cells were pretreated with spautin-1 for 2 h, followed by Nic (10 µM) for 24, 48, and 72 h and cell viability 
was assessed by Calcein-AM assay Values are expressed as mean ± SEM (n = 3), p values: ***p < 0.001, ***p < 0.001, *p < 0.05 vs con-
trol (24 h); p values: ###p < 0.001, ##p < 0.001, #p < 0.05 vs control (48 h); p values: $$$p < 0.001, $$p < 0.001, $p < 0.05 vs control (72 h). 




Figure S9. Demonstration of the effect of Nic on the β-catenin signaling molecules in normal pancreatic cell line (HPNE) and colo-
rectal cancer cell line (LS-180). Representative western blot images showing the expression of β-catenin (active), p-Gsk3β, and 
Gsk3β in normal pancreatic cell line HPNE and colorectal cell line LS180 -treated with Nic (5 µM or10 µM) for 24 h. Membrane was 
stripped and reprobed with β-actin for internal loading control. 
 
Figure 10. Demonstration of the effect of Nic on the expression of Hh signaling ligand (Shh) in PC cell lines. Representative western 
blot images showing the expression of Shh in PC cells treated with Nic (10 µM) for different time points. β-actin used as an internal 
loading control. 
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Table S1. List of primary antibodies. 
 
 




1 cleaved PARP 9542 
Cell Signaling 
Technology 
1:1000  WB 
2 cleaved caspase 9 20750 
Cell Signaling 
Technology 
1:1000  WB 
3 LC3AI/BII 4108 
Cell Signaling 
Technology 
1:2000  WB 
4 LC3 AP1802a Abgent 1:200 IF 
5 Beclin-1 sc-11427 
Santa Cruz 
Biotechnology 
1:2000  WB 






















1:1000; 1:200 WB; IF 
11 p27 kip1 2552S 
Cell Signaling 
Technology 
1: 1000 WB 








14 p- Gsk3β (Ser9) 9322 
Cell Signaling 
Technology 
1:1000; 1:100 WB; IF 












18 Gli3 19949-1-AP 
Thermo Fisher 
Scientific 
1:1000; 1:100 WB; IF 
19 Gli1 sc-515781 
Santa Cruz 
Biotechnology 
1:1000; 1:100 WB; IF 












23 N-cadherin  ab76011 abcam 1:1000 WB 
24 Claudin-1 ab15098 abcam 1:1000 WB 
















29 FAP-1 ab 53066 abcam 1:1000 WB 




Table S2. List of secondary antibodies. 
S.No. Secondary antibody (Ab) Cat# No. Manufacturer Secondary Ab Dilution used 
1 Goat anti-rabbit IgG-HRP 31460 Invitrogen  1:5000 
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2 Goat anti-mouse IgG-HRP 31430 Invitrogen 1:5000 
3 
Goat anti-Rabbit IgG (H+L) 




Invitrogen 1:200; 1:500 
4 
Goat anti-Mouse IgG (H+L) 
Secondary Antibody, Alexa 
Fluor 568 
A-11004 Invitrogen 1:200; 1:500 
5 
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, Alexa 
Fluor 488 
A-11034 Invitrogen 1:200 
 
